Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Grifols S.A. (GRFS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,427,986
  • Shares Outstanding, K 682,820
  • Annual Sales, $ 4,881 M
  • Annual Income, $ 749,050 K
  • 36-Month Beta 1.18
  • Price/Sales 2.90
  • Price/Cash Flow 14.29
  • Price/Book 2.93

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 0.29
  • Number of Estimates 3
  • High Estimate 0.31
  • Low Estimate 0.28
  • Prior Year 0.29
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.47 +20.15%
on 10/24/18
21.67 -3.14%
on 11/08/18
+1.37 (+6.98%)
since 10/12/18
3-Month
17.47 +20.15%
on 10/24/18
21.99 -4.55%
on 08/29/18
+0.30 (+1.45%)
since 08/14/18
52-Week
17.47 +20.15%
on 10/24/18
25.18 -16.64%
on 01/23/18
-2.19 (-9.45%)
since 11/14/17

Most Recent Stories

More News
Grifols demonstrates a significant reduction (61%) in the progression of moderate Alzheimer's disease using its AMBAR treatment protocol

Presenting the study results, Antonio Páez, M.D., Grifols Medical Director and Head of the AMBAR Clinical Program confirmed that the analysis of AMBAR data in moderate patients has shown positive, highly...

GRFS : 20.99 (-0.66%)
GRF : 7.53 (+1.76%)
FDA Approves Grifols ID CORE XT Test For Molecular Red Blood Cell Typing

Test Offers Shortest Time to Reportable Results For US Hospitals, Reference Labs and Blood Centers

GRFS : 20.99 (-0.66%)
GRF : 7.53 (+1.76%)
FDA Approves Grifols ID CORE XT Test For Molecular Red Blood Cell Typing

Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, received approval from the U.S....

GRFS : 20.99 (-0.66%)
GRF : 7.53 (+1.76%)
Grifols (GRFS) Surges: Stock Moves 5.4% Higher

Grifols (GRFS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

BCRX : 6.99 (-2.10%)
GRFS : 20.99 (-0.66%)
Grifols Announces the Opening of Biotest Pharmaceuticals Corporation's Newest Plasma Donor Center in Bowling Green, Ohio

Grifols is pleased to announce the opening of its newest Biotest Pharmaceuticals Corporation (BPC) plasma donor center located at 1616 East Wooster Street, Bowling Green, Ohio. The 13,000 square foot state-of-the-art...

GRFS : 20.99 (-0.66%)
GRF : 7.53 (+1.76%)
Is Grifols, S.A. (GRFS) a Great Stock for Value Investors?

Is Grifols, S.A. (GRFS) a great pick from the value investor's perspective right now? Read on to know more.

GRFS : 20.99 (-0.66%)
Grifols Achieves Key Milestone with FDA Approval of the New Consolidated Manufacturing Facility (CMF) for Production of Recombinant Proteins

Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a global healthcare company with a history of more than 75 years of improving people's health and well-being and a leader in the development of innovative...

GRFS : 20.99 (-0.66%)
GRF : 7.53 (+1.76%)
Procleix® Zika Virus Assay Approved by the FDA for Blood Screening on the Procleix® Panther® System

Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, today announced that the U.S....

GRFS : 20.99 (-0.66%)
GRF : 7.53 (+1.76%)
Grifols Expands its Blood Typing Solutions Portfolio in the United States with Antisera Reagents

Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, today announced the expansion...

GRFS : 20.99 (-0.66%)
GRF : 7.53 (+1.76%)
Report: Exploring Fundamental Drivers Behind Itau Unibanco Holding S.A, Weibo, Redhill Biopharma, Shenandoah Telecommunications, Grifols, S.A, and Orthofix International N.V -- New Horizons, Emerging Trends, and Upcoming Developments

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Itau Unibanco Holding S.A....

RDHL : 8.33 (-10.91%)
OFIX : 57.41 (-2.81%)
SHEN : 45.85 (+2.62%)
GRFS : 20.99 (-0.66%)
ITUB : 13.48 (+1.66%)
WB : 57.17 (+3.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade GRFS with:

Business Summary

Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience...

See More

Key Turning Points

2nd Resistance Point 21.51
1st Resistance Point 21.25
Last Price 20.99
1st Support Level 20.84
2nd Support Level 20.68

See More

52-Week High 25.18
Fibonacci 61.8% 22.23
Fibonacci 50% 21.33
Last Price 20.99
Fibonacci 38.2% 20.42
52-Week Low 17.47

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar